GT Biopharma Inc. (GTBP) financial statements (2020 and earlier)
Company profile
| Business Address |
310 N. WESTLAKE BLVD. WESTLAKE VILLAGE, CA 91362 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 0 | 0 | 1 | 0 | 0 | ||
| Cash and cash equivalents | 0 | 0 | 1 | 0 | 0 | ||
| Prepaid expense | 0 | 0 | 0 | 0 | |||
| Total current assets: | 0 | 0 | 1 | 0 | 0 | ||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | |||
| Intangible assets, net (including goodwill), including: | 25 | 254 | |||||
| Other undisclosed intangible assets, net (including goodwill) | 25 | 254 | |||||
| Deposits noncurrent assets | 0 | 0 | 0 | ||||
| Other undisclosed noncurrent assets | 0 | ||||||
| Total noncurrent assets: | 0 | 25 | 254 | 0 | 0 | ||
| TOTAL ASSETS: | 0 | 25 | 254 | 0 | 0 | ||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 6 | 3 | 3 | 6 | 8 | ||
| Accounts payable | 2 | 2 | 3 | 2 | 1 | ||
| Accrued liabilities | 2 | 1 | 0 | 0 | 4 | ||
| Interest and dividends payable | 2 | 4 | 2 | ||||
| Debt | 13 | 11 | 1 | 1 | |||
| Deferred rent credit | 0 | ✕ | ✕ | ✕ | |||
| Due to related parties | 0 | ||||||
| Other undisclosed current liabilities | 0 | 0 | 0 | 12 | 41 | ||
| Total current liabilities: | 20 | 14 | 3 | 19 | 50 | ||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 1 | ||||||
| Long-term debt, excluding current maturities | 1 | ||||||
| Total noncurrent liabilities: | 1 | ||||||
| Total liabilities: | 20 | 14 | 3 | 19 | 51 | ||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | (19) | 11 | 252 | (19) | (51) | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 548 | 540 | 520 | 106 | 84 | ||
| Accumulated deficit | (567) | (529) | (268) | (125) | (134) | ||
| Other undisclosed stockholders' equity attributable to parent | (0) | (0) | (0) | (0) | (0) | ||
| Total stockholders' equity: | (19) | 11 | 252 | (19) | (51) | ||
| TOTAL LIABILITIES AND EQUITY: | 0 | 25 | 254 | 0 | 0 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|
| Gross profit: | 0 | |||||
| Operating expenses | (16) | (250) | (136) | (9) | (9) | |
| Operating loss: | (16) | (250) | (136) | (9) | (9) | |
| Nonoperating income (expense) | (23) | (9) | (8) | 19 | (13) | |
| Investment income, nonoperating | (5) | (229) | ||||
| Interest and debt expense | (2) | (9) | (9) | (7) | (17) | |
| Income (loss) from continuing operations before equity method investments, income taxes: | (41) | (268) | (152) | 3 | (39) | |
| Other undisclosed income from continuing operations before income taxes | 2 | 9 | 9 | 7 | 17 | |
| Net income (loss) available to common stockholders, diluted: | (39) | (259) | (143) | 10 | (21) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (39) | (259) | (143) | 10 | (21) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (39) | (259) | (143) | 10 | (21) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.